# Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

> **NCT06302062** · PHASE1 · RECRUITING · sponsor: **Guangzhou FineImmune Biotechnology Co., LTD.** · enrollment: 23 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Tumor Associated Lymph Node T Cell
- Immunotherapy

## Interventions

- **DRUG:** Tumor Associated Lymph node T cell
- **DRUG:** cyclophosphamide
- **DRUG:** IL-2
- **DRUG:** Serplulimab Injection

## Key facts

- **NCT ID:** NCT06302062
- **Lead sponsor:** Guangzhou FineImmune Biotechnology Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-06
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06302062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06302062, "Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06302062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*